ORIENT-12 Study demonstrates adding sintilimab to gemcitabine/platinum has clinical benefit

chemotherapy
Credit: CC0 Public Domain

Adding sintilimab to a regimen of gemcitabine and platinum demonstrates clinical benefit over gemcitabine and platinum alone as first-line therapy in patients with locally advanced or metastatic squamous cell non-small cell lung cancer, according to a study published in the Journal of Thoracic Oncology, the official journal of the International Association for the Study of Lung Cancer.

The standard chemotherapy for squamous NSCLC (sqNSCLC), includes plus gemcitabine. sintilimab, an anti-PD-1 antibody, plus platinum/gemcitabine, has shown encouraging efficacy as first-line therapy for sqNSCLC in the phase III study ECOG 1594. Platinum/gemcitabine is another standard regimen of chemotherapy for sqNSCLC and is commonly used in Asia.

Led by Caicun Zhou, MD, Ph.D., from Shanghai Pulmonary Hospital in Shanghai, China, the researchers conducted a randomized, double-blind, phase 3 study to further compare the efficacy and safety of sintilimab with placebo, both in combination with gemcitabine/platinum.

Dr. Zhou and his co-researchers randomized patients with locally advanced or metastatic sqNSCLC and without EGFR-sensitive mutations or ALK rearrangements. Overall, researchers screened 543 patients from 42 centers throughout China. Of those, 357 patients were randomized into the sintilimab-gemcitabine/platinum group (n=179) and the placebo-gemcitabine/platinum group (n=178).

The primary endpoint was progression-free survival (defined as the time from randomization to the first disease progression or death from any cause), as assessed by the independent radiographic review committee.

After a median follow-up period of 12.9 months, in the sintilimab-gemcitabine/platinum group continued to demonstrate a meaningful improvement in over the placebo-gemcitabine/platinum group (HR 0.536 [95% CI 0.422-0.681]; p<0.00001).

The incidence of treatment-emergent adverse events leading to death was 4.5 % and 6.7 % in the sintilimab-gemcitabine/platinum group and the placebo-gemcitabine/platinum group, respectively.

"In this study, the risk of disease progression or death was reduced by 37.9 % at interim analysis and by 46.4 % at updated analysis," Dr. Zhou said. "The results from ORIENT-12 could provide a new option for combination therapy in this patient population."


Explore further

Addition of sintilimab to pemetrexed and platinum improved progression-free survival

More information: Caicun Zhou et al, Sintilimab plus platinum and gemcitabine as first-line treatment for advanced or metastatic squamous non-small-cell lung cancer: results from a randomized, double-blind, phase 3 trial (ORIENT-12), Journal of Thoracic Oncology (2021). DOI: 10.1016/j.jtho.2021.04.011
Journal information: Journal of Thoracic Oncology

Provided by International Association for the Study of Lung Cancer
Citation: ORIENT-12 Study demonstrates adding sintilimab to gemcitabine/platinum has clinical benefit (2021, May 25) retrieved 17 September 2021 from https://medicalxpress.com/news/2021-05-orient-adding-sintilimab-gemcitabineplatinum-clinical.html
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.
1 shares

Feedback to editors